[1]何旭梅,陈 红,胡乔玲,等.化痰散结法治疗亚急性甲状腺炎疗效及对患者炎症因子的影响*[J].陕西中医,2020,(8):1104.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.024]
　HE Xumei,CHEN Hong,HU Qiaoling,et al.Therapeutic effect of Huatan Sanjie method on subacute thyroiditis and its effect on inflammatory factors[J].,2020,(8):1104.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.024]
点击复制

化痰散结法治疗亚急性甲状腺炎疗效及对患者炎症因子的影响*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年8期
页码:
1104
栏目:
临床研究
出版日期:
2020-08-05

文章信息/Info

Title:
Therapeutic effect of Huatan Sanjie method on subacute thyroiditis and its effect on inflammatory factors
作者:
何旭梅; 陈 红; 胡乔玲; 刘佳维; 尚聪颖
武汉市第一医院内分泌科(武汉 430022)
Author(s):
HE Xumei; CHEN Hong; HU Qiaoling; et al.
Department of Endocrinology,Wuhan No.1 Hospital(Wuhan 430022)
关键词:
化痰散结法;  亚急性甲状腺炎;  甲状腺功能;  肿瘤坏死因子-α;  白细胞介素-2;  白细胞介素-3
Keywords:
Huatan Sanjie method;  Subacute thyroiditis;  Thyroid function;  TNF-α;  IL-2;  IL-3
分类号:
R581.4
DOI:
DOI:10.3969/j.issn.1000-7369.2020.08.024
文献标志码:
A
摘要:
目的:探讨化痰散结法治疗亚急性甲状腺炎的近期疗效及对患者血清炎症因子的影响。方法:选取亚急性甲状腺炎患者80例。随机分为对照组和观察组各40例。对照组给予醋酸泼尼松治疗,观察组在对照组用药基础上给予化痰散结法治疗。比较两组治疗前后甲状腺功能指标(FT3、FT4、TSH)、血清炎症因子(TNF-α、IL-2、IL-3)变化、临床疗效及生活质量情况。结果:治疗后2、4、8周,两组患者中医症状积分均明显下降,且观察组比对照组下降更明显(P<0.05)。治疗前,两组血清FT3、FT4、TSH、TNF-α、IL-2、IL-3比较差异无统计学意义(P>0.05); 两组治疗后FT3、FT4、TNF-α均降低,TSH、IL-2、IL-3均升高(P<0.05); 观察组治疗后FT3、FT4、TNF-α均低于对照组,TSH、IL-2、IL-3均高于对照组(P<0.05); 两组治疗期间均未出现明显不良反应,观察组总有效率95.00%高于对照组77.50%(P<0.05)。观察组治疗后生活质量明显优于对照组(P<0.05)。结论:化痰散结法可显著改善亚急性甲状腺炎患者甲状腺功能,降低血清TNF-α水平,提高IL-2、IL-3水平,临床疗效满意。
Abstract:
Objective:To investigate the short-term effect of Huatan Sanjie method in the treatment of subacute thyroiditis and its effect on serum inflammatory factors.Methods:80 patients with subacute thyroiditis were selected.Randomly divided into control group and observation group,40 cases each.The control group was treated with prednisone acetate,and the observation group was treated with Huatan Sanjie method on the basis of the control group.Results:After 2,4 and 8 weeks of treatment,the TCM symptom scores of the two groups decreased significantly,and the observation group decreased more significantly than the control group(P<0.05).After treatment,FT3,FT4 and TNF-α decreased,TSH,IL-2 and IL-3 increased in the two groups(P<0.05); after treatment,FT3,FT4 and TNF-α in the observation group were lower than those in the control group,TSH,IL-2 and IL-3 were higher than those in the control group(P<0.05); during the treatment,there were no significant adverse reactions in the two groups.The total effective rate of the observation group was 95.00% higher than that of the control group(P<0.05).The quality of life in the observation group was significantly better than that in the control group(P<0.05).Conclusion:Huatan Sanjie method can significantly improve the thyroid function of patients with subacute thyroiditis,reduce the level of serum TNF-α,and improve the level of IL-2 and IL-3.The clinical effect is satisfactory,which is worthy of application and promotion.

参考文献/References:

[1] 陆西宛,朱丽华,黄 煌,等.小柴胡汤加味治疗亚急性甲状腺炎46例临床观察[J].中国实验方剂学杂志,2018,24(22):153-158.
[2] 石 英.小剂量糖皮质激素续贯减量法联合消炎痛续贯增量法治疗亚急性甲状腺炎的应用效果观察[J].中国实用乡村医生杂志,2019,26(6):64-66.
[3] 樊启辉.不同剂量泼尼松对亚急性甲状腺炎患者临床疗效及不良反应的影响比较[J].当代医学,2019,25(22):76-78.
[4] 魏海伦.甲状腺内注射激素与环磷酰胺双重免疫调节对亚急性甲状腺炎的治疗效果研究[J].现代医学与健康研究电子杂志,2018,2(9):53.
[5] 刘斐斐,熊莉华.中药内服外敷治疗亚急性甲状腺炎[J].四川中医,2018,12(4):160-161.
[6] 中华医学会内分泌学会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南-甲状腺结节[J].中华内科杂志,2008,47(10):867-868.
[7] 国家中医药管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:226-228.
[8] 卢继东,吴 松,梁凤霞,等.隔姜灸联合糖皮质激素治疗亚急性甲状腺炎:随机对照研究[J].中国针灸,2016,36(1):7-11.
[9] 薛 霞,徐旭娟,顾志峰,等.中文版甲状腺疾病患者生活质量问卷简明版的信效度检验 [J].中国全科医学,2017,20(17):2111-2117.
[10] 胡 茗,钱 敏,王一峰,等.血清T3/T4在亚急性甲状腺炎与Graves'病鉴别诊断中的价值[J].陕西医学杂志,2019,48(6):807-809.
[11] 郭同兰,韩 冬,郝慧钧.蒲地蓝口服液联合小剂量强的松治疗亚急性甲状腺炎的临床观察[J].中外医学研究,2017,15(24):7-8.
[12] 洪 兵,陈丽娟,殷学超,等.柴胡清肝汤对亚急性甲状腺炎毒热炽盛证患者血清促炎症因子水平的影响[J].现代中西医结合杂志,2015,24(14):1504-1506.
[13] 范景丽,马玉琴,汪春雷,等.121 例亚急性甲状腺炎患者流行病学及临床特点的回顾性分析[J].中华地方病学杂志,2017,36(5):338-341.
[14] 石元同,张思德.夏枯草胶囊联合优甲乐治疗桥本甲状腺炎临床疗效[J].陕西中医,2017,38(11):1562-1563.
[15] 王兰芬,吴深涛.吴深涛治疗单纯性甲状腺肿的用药规律分析[J].湖南中医杂志,2018,34(7):39-41.

备注/Memo

备注/Memo:
*湖北省卫生健康委员会科研项目(WJ2018F038)
更新日期/Last Update: 2020-08-10